Beatriz Llamusí: "The main goal is to get our treatment to patients"

ARTHEx Biotech, a spin-off company of the Universitat de València, has been awarded with the Best Startup 2023 (12,000 euros to invest in the company). It is focused on the development of a treatment against muscular dystrophy type 1 based on microRNA inhibitors. Its first clinical trial in patients will begin in January 2024 and to date it has raised €5 million in public funding and €49 million in private investment rounds. Beatriz Llamusí, Chief Scientific Officer of ARTHEx Biotech explains to the Las Provincias team where the idea came from and how it has been the path to bring it to fruition.

Complete news in Las Provincias.